Molnupiravir for the treatment of COVID-19 outpatients: An updated meta-analysis.
J Microbiol Immunol Infect
; 57(3): 396-402, 2024 Jun.
Article
em En
| MEDLINE
| ID: mdl-38555274
ABSTRACT
BACKGROUND:
The majority of available data on molnupiravir come from an unvaccinated COVID-19 population. Therefore, we conducted this meta-analysis to integrate evidence from recent randomized controlled trials (RCTs) as well as observational studies stratified by vaccination status to determine the clinical efficacy and safety of molnupiravir in COVID-19 outpatients.METHODS:
We searched PubMed, Embase, the Cochrane Library, medRxiv, and ClinicalTrials.gov from inception to November 2023. We conducted our meta-analysis using RevMan 5.4 with risk ratio (RR) as the effect measure.RESULTS:
We included 8 RCTs and 5 observational studies in our meta-analysis. Molnupiravir reduced the risk of all-cause mortality (RR 0.28; 95% CI 0.20-0.79, I2 = 0%) but did not decrease the hospitalization rate (RR 0.67; 95% CI 0.45-1.00, I2 = 53%) in the overall population; in the immunized population, no benefits were observed. Molnupiravir lowered the rate of no recovery (RR 0.78; 95% CI 0.76-0.81, I2 = 0%) and increased virological clearance at day 5 (RR 2.68; 95% CI 1.94-4.22, I2 = 85%). There was no increase in the incidence of adverse events.CONCLUSIONS:
Molnupiravir does not decrease mortality and hospitalization rates in immunized patients with COVID-19. However, it does shorten the disease course and increases the recovery rate. The use of molnupiravir will need to be considered on a case-by-case basis in the context of the prevailing social circumstances, the resource setting, drug costs, and the healthcare burden.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Antivirais
/
Citidina
/
SARS-CoV-2
/
COVID-19
/
Tratamento Farmacológico da COVID-19
/
Hidroxilaminas
Limite:
Humans
Idioma:
En
Revista:
J Microbiol Immunol Infect
Assunto da revista:
ALERGIA E IMUNOLOGIA
/
MICROBIOLOGIA
Ano de publicação:
2024
Tipo de documento:
Article